-
Testosterone in Older Men: Is Low Normal Too Low?, CT Pulmonary Angiography as Good as Ventilation- perfusion Scanning for Suspected Pulmonary Embolus, Vertebral Fracture Begets Vertebral Fractureand
-
The 12-lead ECG and lead II rhythm strip in the Figure were obtained from a 59-year old man several days after coronary bypass. He complained of postitional chest pain. How would you interpret his ECG given this clinical context?
-
Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
-
Patients with a first VTE event occurring in association with a reversible or time-limited risk factor should be treated with anticoagulants for at least three months, whereas patients with a first PE should be treated for at least six to 12 months; in fact, a case can be made for indefinite anticoagulant therapy in PE patients who have a great concern about recurrent PE and/or who are minimally concerned about the bleeding risk of anticoagulant therapy and the need for frequent determinations of the INR.
-
Female physicians have more than twice the rate of suicide as other professional women and are proportionally at greater risk compared with their male physician counterparts.
-
It's time to redouble efforts to stem adolescent pregnancy. Preliminary birth statistics released by the Centers for Disease Control and Prevention indicate the U.S. birth rate rose by 3% between 2005 and 2006 among females 15-19 after dropping 34% between 1991 and 2005.
-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
-
Tick off the contraceptive options now available at your clinic. If you are a provider at a university health center, chances are your list may be shorter than it was in 2007.
-
With results just published for a Phase I clinical trial and data for a Phase I/II trial in analysis, developers of what is being dubbed the Invisible Condom are looking toward initiation of a Phase III randomized controlled trial to test the safety and efficacy of the potential microbicide.
